1. Market Research
  2. > Biotechnology
  3. > Genomics Market Trends
  4. > Vital Signs - Healthcare News - The Analyst's Perspective February 2014 Issue

Amgen and Illumina Enter Agreement to Develop Oncology Companion Diagnostic Test

The Californian sequencing instrumentation leader, Illumina, entered into a partnership with Amgen to develop and commercialize a multigene next generation sequencing (NGS) based companion diagnostic test for the targeted drug Vectibix in metastatic colorectal cancer. This partnership marks Illumina’s entry into the NGS personalized medicine segment.

The Analyst’s Perspective by Divyaa Ravishankar, Senior Industry Analyst, Life Science North America

Various life science tools manufacturers have entered the companion diagnostic market segment in the last two years. The Amgen-Illumina partnership will be developing one of the first NGS-based companion diagnostic assays. The partnership leverages Illumina’s market leadership in NGS research platforms. The partnership also delivers a geographic advantage in the U.S. and Europe, which leads to an easier roadmap to address regulatory challenges. Illumina’s MiSeq sequencer has lowered the cost of sequencing relative to the competition, making it a suitable platform to develop the multi-gene test. Amgen partnered with Illumina for its strong track record in the commercialization of novel personalized medicine products. Examples include a partnership with DxS in 2008 for the KRAS companion diagnostic test and a partnership with Dako in 2012 for another companion diagnostic test associated with a rare cancer treatment.
NGS enables patient tumor genetic profiling and the NGS market segment is rapidly moving toward clinical diagnostics for its advantages to detect a large number of mutations simultaneously and affordably. Resulting from this work, physicians can choose the best possible treatment option personalized to the patient. In the next few years, Illumina will reap benefits from this novel diagnostic test, which will position the company in the high growth companion diagnostic segment.

Nestlé Launches New Dermatology Subsidiary Through Complete Acquisition of Galderma

Nestlé has made another strategic move in their transition toward a more healthcare focused company, with the full acquisition of dermatology specialty company, Galderma. Nestlé will fund this transaction with the sale of 48.5 million shares of Loréal in which Nestlé gains a 50% stake in Galderma from Loréal, resulting in 100% ownership of Galderma. Galderma will be the foundation of a new subsidiary, Nestlé Skin Health S.A. The transaction is pending regulatory approval.

Table Of Contents

Vital Signs - Healthcare News - The Analyst's Perspective February 2014 Issue
Amgen and Illumina Enter Agreement to Develop Oncology Companion Diagnostic Test
Nestle Launches New Dermatology Subsidiary through Complete Acquisition of Galderma
Myriad Genetics Acquires Crescendo Bioscience for $270 Million
Fluidigm Corporation to Acquire DVS Sciences

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
The Chinese Market for DNA Sequencing

The Chinese Market for DNA Sequencing

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Learn about recent advances and trends in the Chinese sequencing industry and market. - Analyze the Chinese sequencing market by workflow, including sample preparation products, ...

Next Generation Sequencing (NGS) Global market - Forecast to 2022

Next Generation Sequencing (NGS) Global market - Forecast to 2022

  • $ 4950
  • Industry report
  • November 2016
  • by IQ4I Research & Consultancy Pvt. Ltd

A decade has gone, since the first human genome has been sequenced and sequencing technology has come a long way from the time of introduction as Next generation Sequencing (NGS) has revolutionized the ...

Global Precision Medicine Market

Global Precision Medicine Market

  • $ 4250
  • Industry report
  • December 2016
  • by Mordor Intelligence LLP

The global precision medicine market is expected to reach close to USD 40 billion by the end of 2016, gradually growing at an estimated CAGR of 10.3% by 2021. Precision medicine is an emerging approach ...


Download Unlimited Documents from Trusted Public Sources

The future of the Genome Sequencing Industry

  • January 2017
    2 pages
  • Genome Sequenci...  

    Genetic  

View report >

Genome Sequencing Forecast

  • January 2017
    2 pages
  • Genome Sequenci...  

View report >

Genomics Industry in the US

  • January 2017
    4 pages
  • Genomics  

  • United States  

View report >

Genomics Industry

19 days ago

Genomics Industry

20 days ago

Related Market Segments :

Genome Sequencing

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.